US009409662B2

(12) **United States Patent**
Zhao et al.

(10) **Patent No.: US 9,409,662 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **FORMULATIONS OF ALBU-BCHE, PREPARATION AND USES THEREOF**

(71) Applicants: **Qinghai Zhao**, North Potomac, MD (US); **Xia Luo**, Rockville, MD (US); **Jason Bock**, North Potomac, MD (US)

(72) Inventors: **Qinghai Zhao**, North Potomac, MD (US); **Xia Luo**, Rockville, MD (US); **Jason Bock**, North Potomac, MD (US)

(73) Assignee: **TEVA PHARMACEUTICAL INDUSTRIES, LTD.**, Petach-Tikva (IL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/155,021**

(22) Filed: **Jan. 14, 2014**

(65) **Prior Publication Data**

US 2014/0199283 A1 Jul. 17, 2014

Related U.S. Application Data

(60) Provisional application No. 61/752,740, filed on Jan. 15, 2013.

(51) **Int. Cl.**

B65B 3/04	(2006.01)
A61J 1/00	(2006.01)
A61K 38/46	(2006.01)
A61K 38/38	(2006.01)

(52) **U.S. Cl.**

CPC ... ***B65B 3/04*** (2013.01); ***A61J 1/00*** (2013.01); ***A61K 38/385*** (2013.01); ***A61K 38/465*** (2013.01); *C07K 2319/00* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,001,625	A	12/1999	Broomfield et al.
6,989,261	B2	1/2006	Watkins et al.
7,045,318	B2	5/2006	Ballance et al.
7,049,121	B2	5/2006	Zhan et al.
7,070,973	B2	7/2006	Lockridge et al.
7,189,690	B2	3/2007	Rosen et al.
7,438,904	B1	10/2008	Zhan et al.
7,482,013	B2	1/2009	Ballance et al.
7,572,764	B2	8/2009	Cohen et al.
7,731,957	B1	6/2010	Zhan et al.
8,108,149	B2	1/2012	Clark et al.
8,211,439	B2	7/2012	Rosen et al.
8,287,859	B2	10/2012	Rosen et al.
8,318,156	B2	11/2012	Landry et al.
8,334,365	B2	12/2012	Rosen et al.
8,541,373	B2	9/2013	Sklair-Tavron et al.
2003/0096401	A1	5/2003	Huse
2003/0153062	A1	8/2003	Watkins et al.
2004/0016005	A1	1/2004	Karatzas et al.
2004/0087014	A1	5/2004	Huse
2004/0120939	A1	6/2004	Watkins et al.
2004/0121970	A1	6/2004	Watkins et al.
2004/0147002	A1	7/2004	Cohen et al.
2004/0168208	A2	8/2004	Karatzas et al.
2005/0136044	A1	6/2005	Watkins et al.
2006/0039870	A1	2/2006	Turner
2006/0063248	A1	3/2006	Lockridge et al.
2007/0259348	A1	11/2007	Phadke et al.
2008/0194481	A1	8/2008	Rosen et al.
2010/0297062	A1	11/2010	Bock et al.
2011/0002888	A1	1/2011	Rosen et al.
2013/0108606	A1	5/2013	Rosen et al.
2014/0162954	A1	6/2014	Brown et al.
2014/0199286	A1	7/2014	Zhao et al.

FOREIGN PATENT DOCUMENTS

EP	0 367 090 B1	1/1994
EP	1 832 599	9/2007
WO	WO 02/46227	6/2002
WO	WO 03/054182	7/2003
WO	WO 2007/146038	12/2007
WO	WO 2009/058322	5/2009
WO	WO 2011/029892	3/2011
WO	WO 2011/071926	6/2011
WO	WO 2011/071926 A1	6/2011
WO	WO 2012/142281	10/2012
WO	WO 2014/113359	7/2014

OTHER PUBLICATIONS

Gao et al. "An albumin-butyrylcholinesterase for cocaine toxicity and addiction: Catalyic and pharmacokinetic properties," Chemico-Biological Interaction, Sep. 25, 2008), vol. 175, pp. 83-87.

International Search Report mailed Apr. 4, 2014 in connection with PCT International Publication No. PCT/US14/11401.

Written Opinion of the International Search Authority mailed Apr. 4, 2014 in connection with PCT International Publication No. PCT/US14/11401.

Frokjaer, Sven, and Daniel E. Otzen (2005) "Protein drug stability: a formulation challenge." Nature Reviews Drug Discovery 4, pp. 298-306.

Gokarn, Yatin R., et al. (2006) "Excipients for protein drugs." Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems pp. 291-306.

Guidance for Industry: Submission of Summary Bioequivalence Data for ANDAs. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Apr. 2009.

(Continued)

Primary Examiner — Paul Holland

(74) *Attorney, Agent, or Firm* — John P. White; Gary J. Gershik; Cooper & Dunham LLP

(57) **ABSTRACT**

The present invention provides an aqueous pharmaceutical composition comprising the fusion protein whose amino acid sequence is set forth as SEQ ID No:1 and an aqueous solution comprising 40 to 60 mM sodium phosphate. The present invention further provides a lyophilized pharmaceutical composition, an reconstituted solution, a sealed package comprising the lyophilized pharmaceutical composition, and a vial comprising the lyophilized pharmaceutical or the reconstituted solution. The present invention also provides a method of producing the lyophilized pharmaceutical composition and the sealed package. The present invention also provides a method of treating a human having cocaine seeking behavior, and methods of using the aqueous pharmaceutical composition and lyophilized pharmaceutical composition.

13 Claims, 10 Drawing Sheets